Phenylethylamine-like properties of baclofen

Area of Science:

• Neuropharmacology
• Psychiatry

Background:

• Tardive dyskinesia is a movement disorder often associated with antipsychotic use.
• Schizophrenia is a chronic mental disorder affecting cognition and behavior.

Purpose of the Study:

• To evaluate the efficacy of baclofen in treating tardive dyskinesia and schizophrenia.
• To investigate the potential side effects and therapeutic outcomes of baclofen.

Main Methods:

• Clinical trial assessing baclofen's effects on patients with tardive dyskinesia and schizophrenia.
• Observation of motor and psychiatric symptoms during baclofen treatment.

Main Results:

• Baclofen showed improvement in trunkal tardive dyskinesia but led to adverse effects.
• No therapeutic benefit was observed in schizophrenia; psychiatric symptoms tended to worsen.
• Observed side effects included irritability, assaultiveness, and auditory hallucinations.

Conclusions:

• Baclofen is not recommended for schizophrenia due to lack of efficacy and potential for worsening symptoms.
• Baclofen may offer limited benefit for specific types of tardive dyskinesia but is limited by side effects.
• The drug's phenylethylamine-like properties may explain its effects on both conditions.